Colchicine is a plant-derived alkaloid used as an anti-inflammatory medicine. Its established uses include treating and preventing attacks of gout and controlling familial Mediterranean fever. It is also used for pericarditis, and certain formulations have regulatory approval for cardiovascular risk reduction. Colchicine acts principally by binding to tubulin and disrupting microtubule function. It has a narrow margin between therapeutic and toxic exposure, making its interactions and elimination important aspects of its clinical use.
Origin and properties
Colchicine occurs naturally in plants including Colchicum autumnale, commonly called autumn crocus or meadow saffron, and Gloriosa superba. Preparations of colchicum plants were used for joint disease long before the active compound was isolated in the nineteenth century. The autumn crocus is not the plant from which culinary saffron is obtained.
Colchicine is a tropolone alkaloid with the molecular formula . Pharmaceutical preparations contain a controlled amount of the purified compound; colchicine-containing plants are poisonous and are not equivalent to medicinal formulations.
Mechanism of action
Colchicine binds to tubulin, the protein that forms microtubules. These dynamic structures participate in intracellular transport, cell movement, secretion, and chromosome separation during cell division. Colchicine inhibits their assembly and alters their dynamics.
Its anti-inflammatory effects involve several functions of the innate immune system, particularly those of neutrophils. It reduces their movement toward inflammatory sites and interferes with activation and release of inflammatory substances. It can also inhibit processes involved in inflammasome activation and the production of inflammatory signals.
In gout, these effects suppress the response to monosodium urate crystals. Colchicine does not lower uric acid concentrations or directly remove existing crystal deposits. It is therefore distinct from urate-lowering medicines. Although it reduces inflammation, it is not a general-purpose pain reliever and is not a nonsteroidal anti-inflammatory drug.
Clinical uses
Gout
Colchicine is used both to treat acute gout attacks and to prevent attacks in particular clinical settings, including the period after urate-lowering treatment begins. Its role is suppression of crystal-induced inflammation rather than correction of the underlying urate excess.
Modern lower-dose regimens have replaced older practices of repeatedly administering colchicine until gastrointestinal toxicity occurred. Dose, timing, organ function, and interacting medicines all affect its safety.
Familial Mediterranean fever
Familial Mediterranean fever is an inherited autoinflammatory disorder characterized by recurrent episodes of fever and inflammation, often involving the abdominal or chest lining and joints. Regular colchicine treatment reduces attacks and substantially lowers the risk of AA amyloidosis, a complication in which an inflammation-associated protein accumulates in tissues and can damage the kidneys.
Some patients have an incomplete response or cannot tolerate colchicine. Its benefit in this disease is principally preventive; it does not reliably stop an established attack immediately.
Pericarditis
Colchicine is used in acute and recurrent pericarditis, usually alongside other anti-inflammatory treatment. Clinical trials have shown that it reduces recurrences in appropriate patient populations. Regulatory approval for this indication varies between jurisdictions.
Cardiovascular disease
Inflammation contributes to atherosclerosis and its complications. Large randomized controlled trials have investigated low-dose colchicine in people with established coronary disease or a recent myocardial infarction.
In 2023, the United States approved a low-dose colchicine product for reducing specified cardiovascular events in adults with established atherosclerotic disease or multiple cardiovascular risk factors. This indication is product- and jurisdiction-specific. Colchicine does not replace treatment directed at cholesterol, blood pressure, or blood clotting.
Pharmacokinetics and interactions
After oral administration, colchicine is absorbed from the gastrointestinal tract and distributes extensively into tissues. Its pharmacokinetics involve both hepatic processing and renal and biliary elimination.
Colchicine is a substrate of the drug-metabolizing enzyme CYP3A4 and the transport protein P-glycoprotein. Medicines that inhibit either pathway can increase colchicine exposure. Important examples include clarithromycin, certain azole antifungals, some antiviral regimens, and ciclosporin. Some combinations have caused fatal toxicity.
Kidney or liver impairment can further increase exposure. Certain combinations with strong inhibitors are contraindicated in patients with such impairment. Medicines associated with muscle injury, including some statins, may also increase the risk of muscle toxicity when used with colchicine.
Adverse effects and toxicity
The most frequent adverse effects are gastrointestinal, particularly diarrhea, nausea, vomiting, and abdominal discomfort. These effects may limit tolerability.
Less common but serious adverse effects include muscle injury, peripheral nerve injury, and suppression of bone marrow function. Toxicity may occur through overdose, accumulation, or drug interactions.
Colchicine has a narrow therapeutic index. Severe poisoning can begin with gastrointestinal symptoms and progress to circulatory failure, abnormal heart rhythms, bone-marrow suppression, and multiple-organ failure. Its interference with microtubules is particularly damaging to rapidly dividing tissues.
There is no routinely available specific antidote. Treatment of severe poisoning is primarily supportive. Dialysis does not effectively remove colchicine because the drug distributes extensively into tissues.
Laboratory and botanical uses
Colchicine is also a research tool for studying microtubules and cell division. By disrupting the mitotic spindle, it can arrest dividing cells in metaphase, facilitating chromosome examination.
In plant breeding and cytogenetics, colchicine can induce chromosome doubling and produce polyploid plants. These experimental applications reflect the same disruption of chromosome separation that contributes to its toxicity in humans.